{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:37:17Z","timestamp":1790375837651,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Bladder cancer (BC) is the second most prevalent genitourinary malignancy worldwide. Treatment options remain limited for patients with Bacillus Calmette\u2013Gu\u00e9rin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). Up to 70% of NMIBC cases harbor fibroblast growth factor receptor 3 (FGFR3) alterations, and FGFR inhibition has shown potential to enhance the efficacy of immune checkpoint inhibitor (ICI). Interferon (IFN)-\u03b3, a cytokine produced by activated T cells and associated with better response to immunotherapy in BC, is a key inducer of PD-L1 expression in the tumor microenvironment. However, the interaction between FGFR inhibitors and IFN-\u03b3-induced PD-L1 expression in FGFR3-activated NMIBC cells remains unclear. Here, we show that FGFR inhibitors significantly reduced IFN-\u03b3-induced PD-L1 expression in NMIBC cells harboring <jats:italic>FGFR3-TACC3<\/jats:italic> fusions. Mechanistically, FGFR inhibitors restored IFN-\u03b3-suppressed SIRT1 expression, promoted LC3B deacetylation and nuclear export, and enhanced autophagy-lysosomal degradation of PD-L1. Blocking autophagy, overexpression SIGMAR1, or inhibiting lysosomal activity significantly reversed PD-L1 degradation. Notably, we demonstrate for the first time that IFN-\u03b3-induced PD-L1 directly binds to the FGFR3 promoter and represses <jats:italic>FGFR3-TACC3<\/jats:italic> transcription\u2013an effect that can be rescued by FGFR inhibitors or PD-L1 knockdown. Functionally, FGFR inhibitors ameliorated PD1\/PD-L1-mediated T cell suppression in co-culture assays. Together, these findings highlight a novel mechanism by which FGFR inhibitors suppress IFN-\u03b3-induced PD-L1 via autophagy and suggest a potential strategy to improve ICI therapy in FGFR3-altered NMIBC.<\/jats:p>","DOI":"10.1038\/s41419-025-07821-8","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T15:59:04Z","timestamp":1751471944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["FGFR inhibitors promote the autophagic degradation of IFN-\u03b3-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4940-4025","authenticated-orcid":false,"given":"Yu-Chen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ying","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Jyun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-466X","authenticated-orcid":false,"given":"Chun-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"7821_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7821_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.euf.2020.01.013","volume":"7","author":"JB John","year":"2021","unstructured":"John JB, Varughese MA, Cooper N, Wong K, Hounsome L, Treece S, et al. Treatment allocation and survival in patients diagnosed with nonmetastatic muscle-invasive bladder cancer: an analysis of a national patient cohort in England. Eur Urol Focus. 2021;7:359\u201365.","journal-title":"Eur Urol Focus"},{"key":"7821_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jgo.2020.02.001","volume":"11","author":"N Mottet","year":"2020","unstructured":"Mottet N, Ribal MJ, Boyle H, De Santis M, Caillet P, Choudhury A, et al. Management of bladder cancer in older patients: position paper of a SIOG Task Force. J Geriatr Oncol. 2020;11:1043\u201353.","journal-title":"J Geriatr Oncol"},{"key":"7821_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline. J Urol. 2017;198:552\u20139.","journal-title":"J Urol"},{"key":"7821_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.eururo.2022.03.009","volume":"82","author":"IE Ertl","year":"2022","unstructured":"Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, et al. Molecular and pharmacological bladder cancer therapy screening: discovery of clofarabine as a highly active compound. Eur Urol. 2022;82:261\u201370.","journal-title":"Eur Urol"},{"key":"7821_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","volume":"64","author":"M Babjuk","year":"2013","unstructured":"Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639\u201353.","journal-title":"Eur Urol"},{"key":"7821_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40273-023-01273-8","volume":"41","author":"DD Joyce","year":"2023","unstructured":"Joyce DD, Sharma V, Williams SB. Cost-effectiveness and economic impact of bladder cancer management: an updated review of the literature. Pharmacoeconomics. 2023;41:751\u201369.","journal-title":"Pharmacoeconomics"},{"key":"7821_CR8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919\u201330.","journal-title":"Lancet Oncol"},{"key":"7821_CR9","doi-asserted-by":"crossref","unstructured":"Okato A, Utsumi T, Ranieri M, Zheng X, Zhou M, Pereira LD, et al. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J Clin Invest. 2024;134:e169241.","DOI":"10.1172\/JCI169241"},{"key":"7821_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104\u201321.","journal-title":"Nat Rev Cancer"},{"key":"7821_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cac2.12602","volume":"44","author":"M Noeraparast","year":"2024","unstructured":"Noeraparast M, Krajina K, Pichler R, Niedersuss-Beke D, Shariat SF, Grunwald V, et al. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. Cancer Commun. 2024;44:1189\u20131208.","journal-title":"Cancer Commun"},{"key":"7821_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"7821_CR13","doi-asserted-by":"crossref","unstructured":"Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016;4:563\u20138.","DOI":"10.1158\/2326-6066.CIR-15-0274"},{"key":"7821_CR14","doi-asserted-by":"crossref","unstructured":"Rose TL, Weir WH, Mayhew GM, Shibata Y, Eulitt P, Uronis JM, et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer. 2021;125:1251\u201360.","DOI":"10.1038\/s41416-021-01488-6"},{"key":"7821_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.eururo.2019.06.025","volume":"76","author":"L Wang","year":"2019","unstructured":"Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, et al. Fibroblast growth factor receptor 3 alterations and response to PD-1\/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. 2019;76:599\u2013603.","journal-title":"Eur Urol"},{"key":"7821_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","volume":"104","author":"FR Lamont","year":"2011","unstructured":"Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer. 2011;104:75\u201382.","journal-title":"Br J Cancer"},{"key":"7821_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research N.","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315\u201322.","journal-title":"Nature"},{"key":"7821_CR18","doi-asserted-by":"crossref","unstructured":"Sarkar S, Ryan EL, Royle SJ. FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle. Open Biol. 2017;7:170080.","DOI":"10.1098\/rsob.170080"},{"key":"7821_CR19","doi-asserted-by":"crossref","unstructured":"Nassar AH, Lundgren K, Pomerantz M, Van Allen E, Harshman L, Choudhury AD, et al. Enrichment of FGFR3-TACC3 fusions in patients with bladder cancer who are young, asian, or have never smoked. JCO Precis Oncol. 2018;2:PO.18.00013.","DOI":"10.1200\/PO.18.00013"},{"key":"7821_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01897-6","volume":"22","author":"K Komura","year":"2023","unstructured":"Komura K, Hirosuna K, Tokushige S, Tsujino T, Nishimura K, Ishida M, et al. The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Mol Cancer. 2023;22:185.","journal-title":"Mol Cancer"},{"key":"7821_CR21","doi-asserted-by":"crossref","unstructured":"Nassar AH, Lundgren K, Kim J, Choueiri TK, Sonpavde GP, Kwiatkowski DJ, et al. Sequential response to fgfr3 inhibition with subsequent exceptional response to atezolizumab in a patient with FGFR3-TACC3 fusion-positive metastatic urothelial carcinoma. JCO Precis Oncol. 2018;2:1\u20136.","DOI":"10.1200\/PO.18.00117"},{"key":"7821_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352.","journal-title":"Immunity"},{"key":"7821_CR23","doi-asserted-by":"crossref","unstructured":"Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-\u03b3: its role in promoting cancer immunoevasion. Int J Mol Sci. 2017;19:89.","DOI":"10.3390\/ijms19010089"},{"key":"7821_CR24","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1158\/1078-0432.CCR-17-3451","volume":"24","author":"BW Higgs","year":"2018","unstructured":"Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, et al. Interferon gamma messenger rna signature in tumor biopsies predicts outcomes in patients with non-small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin Cancer Res. 2018;24:3857\u201366.","journal-title":"Clin Cancer Res"},{"key":"7821_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10:2977.","journal-title":"Nat Commun"},{"key":"7821_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","volume":"82","author":"Y Adachi","year":"2022","unstructured":"Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, et al. Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies. Cancer Res. 2022;82:292\u2013306.","journal-title":"Cancer Res"},{"key":"7821_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","volume":"82","author":"W Jing","year":"2022","unstructured":"Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114\u201329.","journal-title":"Cancer Res"},{"key":"7821_CR28","doi-asserted-by":"publisher","first-page":"55924","DOI":"10.18632\/oncotarget.10482","volume":"7","author":"R Costa","year":"2016","unstructured":"Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, et al. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget. 2016;7:55924\u201338.","journal-title":"Oncotarget"},{"key":"7821_CR29","first-page":"855","volume":"123","author":"BC Parker","year":"2013","unstructured":"Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest. 2013;123:855\u201365.","journal-title":"J Clin Invest"},{"key":"7821_CR30","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/1078-0432.CCR-17-2066","volume":"24","author":"CH Chen","year":"2018","unstructured":"Chen CH, Changou CA, Hsieh TH, Lee YC, Chu CY, Hsu KC, et al. Dual inhibition of PIK3C3 and FGFR as a new therapeutic approach to treat bladder cancer. Clin Cancer Res. 2018;24:1176\u201389.","journal-title":"Clin Cancer Res"},{"key":"7821_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.eururo.2020.08.002","volume":"78","author":"Y Lyou","year":"2020","unstructured":"Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, Petrylak PD, et al. Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1-3 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3-altered advanced\/metastatic urothelial carcinoma. Eur Urol. 2020;78:916\u201324.","journal-title":"Eur Urol"},{"key":"7821_CR32","doi-asserted-by":"crossref","unstructured":"Szklener K, Chmiel P, Michalski A, Ma\u0144dziuk S. New directions and challenges in targeted therapies of advanced bladder cancer: the role of FGFR inhibitors. Cancers (Basel). 2022;14:1416.","DOI":"10.3390\/cancers14061416"},{"key":"7821_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29342-0","volume":"13","author":"JS Holm","year":"2022","unstructured":"Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard AM, Reading JL, et al. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nat Commun. 2022;13:1935.","journal-title":"Nat Commun"},{"key":"7821_CR34","doi-asserted-by":"crossref","unstructured":"Chang CH, Lin BJ, Chen CH, Nguyen NL, Hsieh TH, Su JH, et al. Stellettin B induces cell death in bladder cancer via activating the autophagy\/DAPK2\/apoptosis signaling cascade. Mar Drugs. 2023;21:73.","DOI":"10.3390\/md21020073"},{"key":"7821_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00262-018-2226-9","volume":"67","author":"Y Shi","year":"2018","unstructured":"Shi Y. Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol Immunother. 2018;67:1481\u20139.","journal-title":"Cancer Immunol Immunother"},{"key":"7821_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1541-7786.MCR-17-0166","volume":"16","author":"CM Maher","year":"2018","unstructured":"Maher CM, Thomas JD, Haas DA, Longen CG, Oyer HM, Tong JY, et al. Small-molecule sigma1 modulator induces autophagic degradation of PD-L1. Mol Cancer Res. 2018;16:243\u201355.","journal-title":"Mol Cancer Res"},{"key":"7821_CR37","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.molcel.2014.12.013","volume":"57","author":"R Huang","year":"2015","unstructured":"Huang R, Xu Y, Wan W, Shou X, Qian J, You Z, et al. Deacetylation of nuclear LC3 drives autophagy initiation under starvation. Mol Cell. 2015;57:456\u201366.","journal-title":"Mol Cell"},{"key":"7821_CR38","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/nar\/gkr984","volume":"40","author":"P Li","year":"2012","unstructured":"Li P, Zhao Y, Wu X, Xia M, Fang M, Iwasaki Y, et al. Interferon gamma (IFN-gamma) disrupts energy expenditure and metabolic homeostasis by suppressing SIRT1 transcription. Nucleic Acids Res. 2012;40:1609\u201320.","journal-title":"Nucleic Acids Res"},{"key":"7821_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105741","volume":"170","author":"H Ying","year":"2021","unstructured":"Ying H, Zhang X, Duan Y, Lao M, Xu J, Yang H, et al. Non-cytomembrane PD-L1: an atypical target for cancer. Pharm Res. 2021;170:105741.","journal-title":"Pharm Res"},{"key":"7821_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11:955.","journal-title":"Cell Death Dis"},{"key":"7821_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106562","volume":"146","author":"JE Mann","year":"2023","unstructured":"Mann JE, Smith JD, Kulkarni A, Foltin SK, Scheftz EB, Murray IR, et al. Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma. Oral Oncol. 2023;146:106562.","journal-title":"Oral Oncol"},{"key":"7821_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15:42\u201350.","journal-title":"Nat Chem Biol"},{"key":"7821_CR43","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","volume":"3","author":"H Yao","year":"2019","unstructured":"Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, et al. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours. Nat Biomed Eng. 2019;3:306\u201317.","journal-title":"Nat Biomed Eng"},{"key":"7821_CR44","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-020-0562-4","volume":"22","author":"Y Gao","year":"2020","unstructured":"Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22:1064\u201375.","journal-title":"Nat Cell Biol"},{"key":"7821_CR45","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s00262-022-03176-7","volume":"71","author":"L Qu","year":"2022","unstructured":"Qu L, Jin J, Lou J, Qian C, Lin J, Xu A, et al. The nuclear transportation of PD-L1 and the function in tumor immunity and progression. Cancer Immunol Immunother. 2022;71:2313\u201323.","journal-title":"Cancer Immunol Immunother"},{"key":"7821_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.annonc.2023.09.3116","volume":"35","author":"JWF Catto","year":"2024","unstructured":"Catto JWF, Tran B, Roupret M, Gschwend JE, Loriot Y, Nishiyama H, et al. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. Ann Oncol. 2024;35:98\u2013106.","journal-title":"Ann Oncol"},{"key":"7821_CR47","doi-asserted-by":"publisher","first-page":"S1343","DOI":"10.1016\/j.annonc.2023.10.110","volume":"34","author":"A Vilaseca","year":"2023","unstructured":"Vilaseca A, Jayram G, Raventos C, Shore ND, Zainfeld D, Kang TW, et al. LBA104 first safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt). Ann Oncol. 2023;34:S1343.","journal-title":"Ann Oncol"},{"key":"7821_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.831168","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Liu Y, Wang Y, Chao Y, Zhang J, Jia Y, et al. Regulation of SIRT1 and its roles in inflammation. Front Immunol. 2022;13:831168.","journal-title":"Front Immunol"},{"key":"7821_CR49","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1038\/sj.emboj.7600244","volume":"23","author":"F Yeung","year":"2004","unstructured":"Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23:2369\u201380.","journal-title":"EMBO J"},{"key":"7821_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2021.111394","volume":"150","author":"JY Sung","year":"2021","unstructured":"Sung JY, Kim SG, Kim JR, Choi HC. SIRT1 suppresses cellular senescence and inflammatory cytokine release in human dermal fibroblasts by promoting the deacetylation of NF-kappaB and activating autophagy. Exp Gerontol. 2021;150:111394.","journal-title":"Exp Gerontol"},{"key":"7821_CR51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.bbagrm.2015.11.010","volume":"1859","author":"M Fang","year":"2016","unstructured":"Fang M, Fan Z, Tian W, Zhao Y, Li P, Xu H, et al. HDAC4 mediates IFN-gamma induced disruption of energy expenditure-related gene expression by repressing SIRT1 transcription in skeletal muscle cells. Biochim Biophys Acta. 2016;1859:294\u2013305.","journal-title":"Biochim Biophys Acta"},{"key":"7821_CR52","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv LB. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545\u201358.","journal-title":"Nat Rev Immunol"},{"key":"7821_CR53","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/bmb.20999","volume":"45","author":"E Lacazette","year":"2017","unstructured":"Lacazette E. A laboratory practical illustrating the use of the ChIP-qPCR method in a robust model: estrogen receptor alpha immunoprecipitation using Mcf-7 culture cells. Biochem Mol Biol Educ. 2017;45:152\u201360.","journal-title":"Biochem Mol Biol Educ"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07821-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07821-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07821-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T17:03:13Z","timestamp":1751475793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07821-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7821"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07821-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. This study did not involve human participants or animal subjects; therefore, ethics approval and informed consent for participation and publication are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"485"}}